These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 1742081)

  • 21. Changes in the reactivity and neutralizing activity of a type-specific neutralizing monoclonal antibody induced by interaction of soluble CD4 with gp120.
    Maeda Y; Matsushita S; Hattori T; Murakami T; Takatsuki K
    AIDS Res Hum Retroviruses; 1992 Dec; 8(12):2049-54. PubMed ID: 1493053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions.
    Callahan LN; Phelan M; Mallinson M; Norcross MA
    J Virol; 1991 Mar; 65(3):1543-50. PubMed ID: 1995952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Defective killing activity against gp120/41-expressing human erythroleukaemic K562 cell line by monocytes and natural killer cells from HIV-infected individuals.
    Ahmad A; Menezes J
    AIDS; 1996 Feb; 10(2):143-9. PubMed ID: 8838701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancement of soluble CD4-mediated HIV neutralization and gp 120 binding by CD4 autoantibodies and monoclonal antibodies.
    Moore JP; Sattentau QJ; Clapham PR
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1273-9. PubMed ID: 2078408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.
    Moore JP; McKeating JA; Huang YX; Ashkenazi A; Ho DD
    J Virol; 1992 Jan; 66(1):235-43. PubMed ID: 1727487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro.
    Cordell J; Moore JP; Dean CJ; Klasse PJ; Weiss RA; McKeating JA
    Virology; 1991 Nov; 185(1):72-9. PubMed ID: 1718090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4.
    Orloff SL; Kennedy MS; Belperron AA; Maddon PJ; McDougal JS
    J Virol; 1993 Mar; 67(3):1461-71. PubMed ID: 8437224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative assay for testing susceptibility of HIV isolates to zidovudine and sCD4 (178)-PE40.
    Verhoef J; Gekker G; Erice A; Peterson PK; Balfour HH
    Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):715-21. PubMed ID: 1425730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4.
    Moore JP
    AIDS; 1990 Apr; 4(4):297-305. PubMed ID: 2190604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contact of human immunodeficiency virus type 1-infected and uninfected CD4+ T lymphocytes is highly cytolytic for both cells.
    Heinkelein M; Sopper S; Jassoy C
    J Virol; 1995 Nov; 69(11):6925-31. PubMed ID: 7474110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of T-cell lines expressing functional HIV-1 envelope glycoproteins for evaluation of immune responses in HIV-infected individuals.
    Keler T; Li H; Cloyd MW; Vitale LA; Deo YM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Oct; 13(2):117-26. PubMed ID: 8862276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.
    Corey L; McElrath MJ; Weinhold K; Matthews T; Stablein D; Graham B; Keefer M; Schwartz D; Gorse G
    J Infect Dis; 1998 Feb; 177(2):301-9. PubMed ID: 9466515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals.
    Beddows S; Lister S; Cheingsong R; Bruck C; Weber J
    J Virol; 1999 Feb; 73(2):1740-5. PubMed ID: 9882391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of IgA inhibiting the interaction between gp120 and soluble CD4 receptor in serum and saliva of HIV-1-infected patients.
    Vincent N; Malvoisin E; Pozzetto B; Lucht F; Genin C
    AIDS; 2004 Jan; 18(1):37-43. PubMed ID: 15090827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble CD4 enhances the efficacy of immunotoxins directed against gp41 of the human immunodeficiency virus.
    Pincus SH; McClure J
    Proc Natl Acad Sci U S A; 1993 Jan; 90(1):332-6. PubMed ID: 8419938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liposome targeting to human immunodeficiency virus type 1-infected cells via recombinant soluble CD4 and CD4 immunoadhesin (CD4-IgG).
    Flasher D; Konopka K; Chamow SM; Dazin P; Ashkenazi A; Pretzer E; Düzgünes N
    Biochim Biophys Acta; 1994 Aug; 1194(1):185-96. PubMed ID: 8075135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals.
    Veillette M; Coutu M; Richard J; Batraville LA; Dagher O; Bernard N; Tremblay C; Kaufmann DE; Roger M; Finzi A
    J Virol; 2015 Jan; 89(1):545-51. PubMed ID: 25339767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies.
    Sullivan N; Sun Y; Binley J; Lee J; Barbas CF; Parren PW; Burton DR; Sodroski J
    J Virol; 1998 Aug; 72(8):6332-8. PubMed ID: 9658072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD4-Pseudomonas exotoxin conjugates delay but do not fully inhibit human immunodeficiency virus replication in lymphocytes in vitro.
    Tsubota H; Winkler G; Meade HM; Jakubowski A; Thomas DW; Letvin NL
    J Clin Invest; 1990 Nov; 86(5):1684-9. PubMed ID: 2243139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-HIV effects of CD4-Pseudomonas exotoxin on human lymphocyte and monocyte/macrophage cell lines.
    Ashorn P; Moss B; Berger EA
    Ann N Y Acad Sci; 1990; 616():149-54. PubMed ID: 2078015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.